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Abstract
Background: Guidelines indicate eligibility for lipid lowering drugs, but it is not known to what extent GPs’ follow guidelines
in routine clinical practice or whether additional clinical factors systematically influence their prescribing decisions.
Methods: A retrospective cohort analysis was undertaken using electronic primary care records from 421 UK general
practices. At baseline (May 2008) patients were aged 30 to 74 years, free from cardiovascular disease and not taking lipid
lowering drugs. The outcome was prescription of a lipid lowering drug within the next two years. The proportions of eligible
and ineligible patients prescribed lipid lowering drugs were reported and multivariable logistic regression models were
used to investigate associations between age, sex, cardiovascular risk factors and prescribing.
Results: Of 365,718 patients with complete data, 13.8% (50,558) were prescribed lipid lowering drugs: 28.5% (21,101/74,137)
of those eligible and 10.1% (29,457/291,581) of those ineligible. Only 41.7% (21,101/50,558) of those prescribed lipid
lowering drugs were eligible. In multivariable analysis prescribing was most strongly associated with increasing age (OR for
age $65 years 4.21; 95% CI 4.05–4.39); diabetes (OR 4.49; 95% CI 4.35–4.64); total cholesterol level $7 mmol/L (OR 2.20;
95% CI 2.12–2.29); and $4 blood pressure measurements in the past year (OR 4.24; 95% CI 4.06–4.42). The predictors were
similar in eligible and ineligible patients.
Conclusions: Most lipid lowering drugs for primary prevention are prescribed to ineligible patients. There is underuse of
lipid lowering drugs in eligible patients.
Citation: Wu J, Zhu S, Yao GL, Mohammed MA, Marshall T (2013) Patient Factors Influencing the Prescribing of Lipid Lowering Drugs for Primary Prevention of
Cardiovascular Disease in UK General Practice: A National Retrospective Cohort Study. PLoS ONE 8(7): e67611. doi:10.1371/journal.pone.0067611
Editor: Hamid Reza Baradaran, Iran University of Medical Sciences, Iran
Received November 13, 2012; Accepted May 24, 2013; Published July 26, 2013
Copyright:  2013 Wu et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted
use, distribution, and reproduction in any medium, provided the original author and source are credited.
Funding: Tom Marshall, Guiqing Lily Yao and Jianhua Wu were partly funded by the National Institute for Health Research (NIHR) through the Collaborations for
Leadership in Applied Health Research and Care for Birmingham and Black Country (CLAHRC-BBC) programme. The views expressed in this publication are not
necessarily those of the NIHR, the Department of Health, NHS Partner Trusts, University of Birmingham or the CLAHRC-BBC Management Group. The funders had
no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Competing Interests: The authors have declared that no competing interests exist.
* E-mail: t.p.marshall@bham.ac.uk
Introduction
Statins are known to be highly effective treatments for primary
and secondary prevention of cardiovascular disease [1,2,3,4].
Several guidelines have been issued at national and international
level, recommending the use of statins in all patients who have a
previous history of cardiovascular disease, or who are judged to be
at high risk of developing cardiovascular disease
[5,6,7,8,9,10,11,12,13]. UK guidelines set a treatment threshold
of 20% ten-year CVD risk [8,9,11]. CVD risk is derived using a
modified version of the Framingham risk equation [14], this
requires information on age, gender, smoking status, diabetic
status, systolic blood pressure, total cholesterol and high density
lipoprotein (HDL) cholesterol levels. Risk is further adjusted for
South Asian ethnicity and for family history of premature
coronary heart disease [9,11]. In addition, in UK guidelines
diabetic patients aged over 40 years are considered eligible for
lipid lowering therapy [8,9,10]. Patients with familial hypercho-
lesterolaemia are eligible for lipid lowering drugs, irrespective of
their calculated cardiovascular risk [8,9,15].
The use of calculated CVD risk as a criterion for recommending
preventive drugs has a long history. CVD risk algorithms and
equations have been available since the 1970s [16,17,18,19,20,21].
The first equation from the Framingham cohort study was
published and validated in 1976 [22,23]. As early as 1978 it was
demonstrated that multivariable risk predicted the benefits of
preventive drugs [24]. Nevertheless early European, UK, US and
Canadian lipid lowering guidelines recommended lipid lowering
drugs if total cholesterol levels exceed a threshold, with some
adjustment for the presence of categorical risk factors
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[25,26,27,28]. Recognition that risk (and not cholesterol levels)
predicted benefit was slow to gain acceptance and the concept of
recommending treatment on the basis of CVD risk only emerged
in the 1990s and later [29,30,31]. However, by 1998 UK
guidelines clearly emphasised risk rather than individual risk
factors as the basis for offering preventive drugs [32]. Current UK
guidelines consistently recommended lipid lowering therapy for:
patients whose calculated ten-year risk of CVD is $20%; diabetics
aged $40 years; patients with familial hypercholesterolaemia
[8,9,10,11].
GP decision making may not have kept pace with changes in
thinking around CVD prevention. In a secondary analysis of data
from a UK CVD prevention project GP prescribing of statins in
usual practice was associated with raised total cholesterol levels
and with antihypertensive prescribing but not with other
cardiovascular risk factors [33]. However in a subgroup of patients
assessed by a cardiovascular prevention nurse, prescribing was
associated with all the main cardiovascular risk factors and more
consistent with guidelines. This analysis raised questions about the
patient factors associated with statin prescribing. In the absence of
advice from a specialist nurse, GP prescribing behaviour
systematically diverged from current guidelines: more closely
associated with categorical clinical characteristics than calculated
risk. This behaviour is more consistent with previous than current
CVD prevention guidelines. Understanding which clinical char-
acteristics are associated with prescribing therefore provides
insight into GPs understanding of prevention.
However it is unclear to what extent the findings of this study
apply to other settings as it was confined to six general practices in
a single urban area in the West Midlands in the context of a
specific cardiovascular prevention project.
This present study uses a large dataset of electronic primary
care records from general practices across the UK. It aims to
investigate the prescribing of lipid lowering drugs for patients
without existing cardiovascular disease in relation to their
eligibility under clinical guidelines. We then investigate the
association between patient characteristics and GP prescribing of
lipid lowering drugs in patients without existing cardiovascular
disease.
Methods
Data sources
This is a retrospective cohort study using data from a database
of electronic primary care records: The Health Improvement
Network (THIN). Data are uploaded from UK general practices
that use the VISION computer system and used for research [34].
The National Health Service (NHS) South-East Multi-centre
Research Ethics Committee approved THIN data collection in
2003. Under the terms of this approval the data are anonymised so
that neither individual patients nor individual general practices
can be identified; because of this individual patient consent is not
required analysis of the dataset (nor is it possible since individuals
cannot be identified); studies using pre-collected, anonymised data
must undergo scientific review to ensure appropriate analysis [35].
For this study, further scientific review and ethical approval was
obtained by TM from the National Research Ethics Service for the
NHS (reference 08/H0305/3).
More than 5 million anonymised patients are collected from 421
practices that are broadly representative of UK general practice in
terms of patients’ age and sex, practice size, and geographical
distribution. The database includes coded data on all diagnoses,
consultations, prescriptions, measurements and laboratory inves-
tigations. The analysis included all patients aged between 30 and
74 in the database on 1st May 2008 (the index date) who were not
currently receiving a prescription for a lipid lowering drug and
provided they had at least one year of records prior to the index
date. To avoid the problem of inflation of the denominator
population during periods when deaths are under-recorded,
practice records were excluded if they fell before a period of
acceptable mortality recording [36]. Because the database was
extracted on 1st May 2010 this meant that patients had up to two
years of follow up from the index date.
Exclusions
Only patients without clinical evidence of CVD (myocardial
infarction, ischaemic heart disease, angina, transient ischemic
attack and stroke) before the date of prescribing a lipid lowering
drug or the last date of follow up were included in the analyses
(Figure 1). All patients with CVD are eligible for lipid lowering
treatment [8,9,11]. Factors influencing prescription of lipid
lowering treatment may be different in these patients and it is
not possible to calculate their ten-year cardiovascular risk. They
were therefore excluded and will be the subject of a separate
analysis.
Predictor variables and outcome
Patients’ age (years), sex, practice and quintile of area
deprivation score (Townsend score) [37] based on their residential
postcode were extracted from the dataset. In the database, medical
diagnoses are coded using the Read code classification scheme
[38]. An appropriate diagnostic Read code at any time before the
index date was taken to indicate the presence of the diagnosis at
baseline. The use of antihypertensive drugs was also recorded.
For measurement variables - systolic and diastolic blood
pressure (mm Hg), serum total cholesterol (TC, mmol/L), HDL
cholesterol (HDL, mmol/L) - the most recent records during the
period of follow up were used. These could be up to one year prior
to the index date or the final value during the two years of follow
up. We excluded implausible values of the measurement variables.
The most recent smoking status (non-smoker, ex-smoker and
current smoker) was also included. If no record existed for smoking
in that period, the patient was assumed to be non-smoker.
Previous analyses suggest that the prevalence of smoking in the
THIN database is similar to that seen in other sources and that
those with missing smoking status are likely to be ex-smokers or
non-smokers [39]. Full lists of Read codes used are available from
the authors.
Our dataset did not include all GP contacts but we determined
the number of blood pressure recordings carried out in the last
year of follow up and used this as proxy for frequency of GP visits.
Although we are primarily interested in statin prescribing we
used first prescription of a lipid lowering drug at any point during
the period of follow up as the outcome. This is because GPs may
prescribe another lipid lowering agent instead and are unlikely to
prescribe both. In practice this makes little difference as in
England 93% of prescriptions for lipid lowering drugs are for
statins [40].
Primary analysis and sensitivity analysis including missing
values
Calculating ten-year risk requires knowledge of age, sex,
diabetic status, smoking status, total cholesterol, HDL cholesterol
and systolic blood pressure. Our primary analysis made use of
cases for whom these data were complete. We undertook a
sensitivity analysis using all patients including those with missing
data. Since the absence of lipid levels and blood pressures may be
Factors Influencing Prescribing of Statins
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related to the prescription of a lipid lowering drug, for each of the
missing continuous variables we created a ‘‘missing value’’
category.
Determining cardiovascular risk
Ten-year cardiovascular risk was calculated from each patient’s
risk factors using the modified Framingham equation advocated in
2005 UK guidelines [8]. This method calculates cardiovascular
risk as the sum of coronary heart disease risk and stroke risk,
multiplying by 1.5 for family history of premature coronary heart
disease.
Treatment eligibility
For each patient, treatment eligibility was determined from their
cardiovascular risk, diabetic status, total cholesterol and HDL
cholesterol levels.
For this analysis, patients were considered to be eligible for lipid
lowering drugs they met the relevant criteria in the principal
relevant UK guidelines. This includes Scottish and joint British
guidelines on cardiovascular prevention, NICE guidelines on
diabetes, NICE guidelines on familial hyperlipidaemia and NICE
guidelines on lipid lowering [8,9,10,11,15]. Patients were eligible
for treatment if their ten-year CVD risk was $20% [8,9,11] or if
they were diabetic and aged $40 years [8,9,10]. In addition,
patients were considered eligible for lipid lowering drugs if they
had familial hypercholesterolaemia [8,9,10,11,15]. Familial hy-
percholesterolaemia is poorly coded in electronic primary care
records. We identified patients aged 30 years to 39 years with a
total cholesterol $8.8 mmol/L and aged $40 years with a total
cholesterol $9.3 mmol/L this has a specificity of 0.98 for a
diagnosis of familial hypercholesterolaemia [41]. This definition
may overestimate the prevalence of hypercholesterolaemia, as the
condition affects 1 in 500 of the population [42]. One guideline
also consider all patients whose total cholesterol to HDL
cholesterol ratio is $6 to be eligible for lipid lowering drugs,
therefore these were also considered eligible for treatment [8].
Statistical Analyses
We first describe prescribing in relation to eligibility under UK
clinical guidelines. For subsequent analyses continuous variables
were categorised. Age (years) was categorised into four bands
(#44, 45–54, 55–64 and $65). Total cholesterol was divided into
three categories (,5, 5.0–6.9 and $7 mmol/L) as these thresholds
are used in some local clinical guidelines. Systolic and diastolic
blood pressure were divided into three categories (,140, 140–159
and$160 mm Hg) and (,90, 90–99 and$100 mm Hg). As there
Figure 1. Flow of patients through study.
doi:10.1371/journal.pone.0067611.g001
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are no clinically accepted thresholds for HDL cholesterol (mmol/
L) this was divided into quartiles (#1.2, 1.3–1.4, 1.5–1.7 and
$1.8 mmol/L). The frequency of blood pressure measurements in
the past year was also categorized into 3 levels (0, 1–3 and $4).
In the multivariable logistic model, we included all risk factors.
We also carried out stratified analyses for patients eligible and not
eligible for lipid lowering drugs under UK guidelines in order to
investigate the relationship between predictors in the model and
patient eligibility.
We used robust standard errors throughout to account for
dependency between patients clustered within the same practice.
We also undertook secondary analyses to examine the role of
variation between practices, because some practices may differ in
their overall propensity to prescribe lipid lowering drugs. We
performed all analyses using multilevel random intercept logistic
regression models with patients nested in practices and with robust
standard errors.
To determine whether cardiovascular risk factors might have an
additional influence on prescribing beyond their contribution to
the cardiovascular risk equation, further analysis was undertaken
including ten year cardiovascular risk as well as individual risk
factors.
For the sensitivity analysis using complete cases, an additional
‘‘missing’’ category was created for total cholesterol, HDL
cholesterol, systolic and diastolic blood pressure. It is not possible
to calculate CVD risk for patients with missing blood pressures or
cholesterol measurements, however patients with missing risk
factor data may be identified as eligible for treatment if they are
diabetic and aged$40 years and (if cholesterol levels are available)
they have familial hypercholesterolaemia.
All analyses were performed using SAS version 9.2 for windows
(SAS Institute Inc., Cary, NC).
Results
There were 1,364,383 patients without clinical evidence of
cardiovascular disease who were not on lipid lowering drugs at
baseline, after exclusion of those without records of blood pressure,
total cholesterol or HDL there were 365,718 complete cases for
analysis (Figure 1). Table 1 shows the characteristics of the study
population divided into those eligible and ineligible for lipid
lowering drugs. Overall 6.7% of this untreated cohort was
diabetic, 6.4% had a family history of premature CHD, 16.3%
were current smokers and 99.9% had a record of their smoking
status. In total, 13.8% (50,558/365,718) were prescribed lipid
lowering drugs by the end of the two years of follow up: 28.5%
(21,101/74,137) of those eligible under UK guidelines and 10.1%
(29,457/291,581) of those ineligible. Therefore 41.7% (21,101/
50,558) of those prescribed lipid lowering drugs were eligible.
In univariable analysis increasing age, diabetic status, prescrip-
tion of antihypertensive drugs, frequent blood pressure measure-
ments and eligibility for lipid lowering drugs were all strong
predictors of treatment. Eligible patients were more likely to be
treated than those not eligible. But eligibility because of diabetes in
patients age $40 years or familial hypercholesterolaemia were
much stronger predictors of treatment than eligibility because of a
ten-year CVD risk$20% or a total cholesterol to HDL cholesterol
ratio $6.0. (Table 2)
In multivariable analysis including individual risk factors the
likelihood of a prescription of lipid lowering drugs was most
strongly associated with increasing age (Odds Ratio for age $65
years 4.21; 95% CI 4.05–4.39); diabetes (Odds Ratio 4.49; 95%
CI 4.35–4.64); total cholesterol level (Odds Ratio for total
cholesterol $7 mmol/L 2.20; 95% CI 2.12–2.29); and the
frequency of blood pressure measurements in the past year (Odds
Ratio for $4 measurements 4.24; 95% CI 4.06–4.42). (Table 3)
Other characteristics, such as male sex, receiving a prescription for
antihypertensive drugs, smoking status and family history of
premature coronary heart disease were moderately associated with
prescribing lipid lowering drugs. There was a modest trend
towards increased prescribing to patients in more deprived areas.
Multivariable analyses were also performed separately on
subgroup patients who were eligible and ineligible for lipid
lowering drugs (Table 4). Predictors of treatment were very similar
in eligible and ineligible patients but some characteristics were
more strongly associated with prescribing among ineligible
patients. Among eligible patients the odds ratio for diabetes was
3.41 (95% CI 3.25 to 3.58) and for age $65 years 1.73 (95% CI
1.62 to 2.85). Among ineligible patients the odds ratio for diabetes
was 9.10 (95% CI 8.13 to 10.10) and for age $65 years 6.74 (95%
CI 6.42 to 7.08). Among ineligible patients male sex, receiving a
prescription for antihypertensive drugs, smoking status and family
history of premature coronary heart disease were slightly more
strongly associated with prescribing lipid lowering drugs. A trend
towards increased prescribing to patients from more deprived
areas was present in both eligible and ineligible patients.
Univariable analysis showed a linear relationship between
cardiovascular risk and prescribing lipid lowering drugs, with no
threshold at 20% ten-year CVD risk. (Table 5) Adding 10-year
cardiovascular risk to the individual risk factors model made little
difference to the odds ratios (data not shown).
The analysis was repeated including all 1,364,383 patients. In
this analysis, 27.9% of those eligible and 2.8% of those ineligible
were started on treatment and only 38.2% of those prescribed lipid
lowering drugs were eligible. In multivariable analysis the same
factors predicted prescribing of lipid lowering drugs and odds
ratios for predictors were very similar to those found with the
complete case analysis. The strongest predictors were: increasing
age (OR for age$65 years 4.27; 95% CI 4.12–4.43); diabetes (OR
4.81; 95% CI 4.69–4.93); total cholesterol level $7 mmol/L (OR
2.44; 95% CI 2.36–2.53) and $4 blood pressure measurements in
the past year (OR for 4.29; 95% CI 4.12–4.46). In the analysis
including patients with missing data the predictors of prescribing
were similar in eligible and ineligible patients.
Patients with missing blood pressure or cholesterol measure-
ments were much less likely to be prescribed lipid lowering drugs.
Discussion
Summary of main findings
Over half of patients without cardiovascular disease who were
started on lipid lowering therapy were ineligible for treatment.
Many eligible patients were not started on treatment. Most
ineligible patients who were started on treatment were aged $55
years but not at high risk of CVD. Eligible patients who were non-
diabetic and those with infrequent blood pressure measurements
were unlikely to be started on treatment. The frequency of
opportunities to prescribe appears to influence prescribing. We
found no evidence of inequitable prescribing, as patients in
deprived areas were slightly more likely to be prescribed lipid
lowering drugs. However this finding should be treated with
caution as deprivation was assessed by postcode of residence and
allocated to quintiles.
We found evidence that GP prescribing is systematically
influenced by cardiovascular risk factors – most strongly by older
age, diabetic status and a total cholesterol level$7 mmol/L. There
was no evidence of a threshold effect at 20% ten-year CVD risk.
Frequent blood pressure measurements (a proxy for cardiovascular
Factors Influencing Prescribing of Statins
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related contacts) were also associated with treatment. Although all
guidelines recommend treatment above a risk threshold and there
is universal access to electronic risk calculators in UK primary
care, cardiovascular risk was not the main predictor of prescribing.
The patient characteristics associated with prescribing were similar
in eligible and ineligible patients.
Strengths and limitations of the study
The analysis uses a large dataset of electronic primary care
records from across the whole of the UK and is representative of
usual clinical care in measurement and recording of risk factors.
We determined predictors of physician rather than patient
behaviour as we are unable to identify whether prescribed drugs
were collected or taken.
Absolute contraindications to lipid lowering drugs are uncom-
mon and are unlikely to influence findings. We have no
information on patients’ treatment preferences, which are not
predictable from patients’ age, sex or risk factor status and may not
accord with guideline recommendations [43,44]. However there is
little evidence that general practitioners take account of patients’
preferences when starting preventive treatments [45].
Comparison with existing literature
Our findings concur with previous studies reporting underuse of
statins in primary care and greater prescribing of statins in patients
with more risk factors [46,47]. We confirmed that total cholesterol
level and family history of premature coronary heart disease are
predictors of statin prescribing [33,48,49]. We found no evidence
of socioeconomic inequity in prescribing. There is little gradient in
statin use across UK civil servants of different grades who were
eligible for treatment [50]. Others found higher statin prescribing
in more deprived UK communities [51].
We found diabetes to be a strong predictor of prescribing. Case
vignette studies have demonstrated that both UK and Australian
GPs are more likely to prescribe statins to eligible diabetics than
eligible non-diabetics [52,53].
LDL cholesterol levels above a threshold have been found to be
an important of treatment in eligible patients [54]. Raised LDL
Table 1. Characteristics of the study population subgrouped into patients eligible and ineligible for lipid lowering drugs.
Number (%) of patients in each category taking lipid lowering drugs
Eligible patients Not eligible patients
Characteristics
No lipid lowering drugs
(n =53,036)
Lipid lowering drugs
(n =21,101)
No lipid lowering drugs
(n =262,124)
Lipid lowering drugs
(n=29,457)
Men 41,211 (77.7) 14,980 (71.0) 99,622 (38.1) 13,377 (45.4)
Women 11,825 (22.3) 6,121 (29.0) 162,502 (61.9) 16,080 (54.6)
Age group:
#44 7,730 (14.6) 1,777 (8.4) 63,484 (24.2) 2,447 (8.3)
45–54 11,476 (21.6) 4,770 (22.6) 82,536 (31.5) 6,308 (21.4)
55–64 16,470 (31.1) 7,682 (36.4) 74,703 (28.5) 11,674 (39.6)
$65 17,360 (32.7) 6,872 (32.6) 41,401 (15.8) 9,028 (30.7)
Diabetes:
Yes 12,129 (22.9) 10,030 (47.5) 1,608 (0.6) 555 (1.9)
No 40,907 (77.1) 11,071 (52.5) 260,516 (99.4) 28,902 (98.1)
Family history of CHD:
Yes 4,710 (8.9) 1,897 (9.0) 14,796 (5.6) 2,040 (6.9)
No 48,326 (91.1) 19,204 (91.0) 247,328 (94.4) 27,417 (93.1)
Smoking status:
Non-smoker 16,564 (31.2) 6,452 (30.6) 147,839 (56.4) 14,371 (48.8)
Current smoker 10,507 (19.8) 4,687 (22.2) 38,535 (14.7) 5,790 (19.7)
Former smoker 25,912 (48.9) 9,958 (47.2) 75,409 (28.8) 9,278 (31.5)
Missing data 53 (0.1) 4 (0) 341 (0.1) 18 (0.1)
Total cholesterol (mmol/L): mean (SD) 5.6 (1.2) 5.4 (1.4) 5.4 (0.9) 5.3 (1.2)
HDL cholesterol (mmol/L): mean (SD) 1.1 (0.3) 1.2 (0.3) 1.2 (0.3) 1.5 (0.6)
Systolic BP (mm Hg): mean (SD) 139.2 (15.7) 140.0 (14.8) 132.3 (15.2) 137.3 (14.2)
Diastolic BP (mm Hg): mean (SD) 82.1 (9.2) 82.0 (8.8) 80.3 (9.3) 81.2 (8.5)
Frequency of BP measurements During last year
of follow up:
0 11,873 (22.4) 1,183 (5.6) 78,737 (30.0) 3,084 (10.5)
1–3 32,828 (61.9) 13,799 (65.4) 154,698 (59.0) 19,127 (64.9)
$4 8,335 (15.7) 6,119 (29.0) 28,689 (10.9) 7,246 (24.6)
CVD risk: mean (SD) 20.5% (8.6%) 21.1% (8.7%) 7.4% (5.0%) 10.4% (4.8%)
Note: for total cholesterol, HDL cholesterol, systolic blood pressure, diastolic blood pressure, the mean and standard deviation (SD) are presented for each category.
doi:10.1371/journal.pone.0067611.t001
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cholesterol also predicts treatment in ineligible patients [55].
These echo our findings that total cholesterol levels $7.0 mmol/L
were important predictors of prescribing.
Our finding of a relationship between prescribing and frequency
of consultation is consistent with clinical inertia, a tendency to
delay the decision to prescribe until the next visit [49,56]. As
patients aged 30 to 74 consult on average 5.6 times per year it is
Table 2. Univariable analysis of factors associated with
prescribing lipid lowering drugs.
Univariable models Patients (n=365,718)
OR 95% CI P value
Age group:
#44 1 ,0.001
45–54 2.02 1.95–2.10
55–64 3.76 3.63–3.89
$65 4.87 4.70–5.05
Gender (Men vs Women) 1.59 1.56–1.62 ,0.001
Smoking status* 1.54 1.51–1.57 ,0.001
Diabetes* 6.04 5.87–6.21 ,0.001
Family history of CHD* 1.27 1.23–1.32 ,0.001
Antihypertensive drugs use* 2.65 2.60–2.70 ,0.001
Deprivation (Townsend fifth):
1 (least deprived) 1 ,0.001
2 1.10 1.07–1.13
3 1.09 1.06–1.12
4 1.21 1.18–1.25
5 (most deprived) 1.30 1.25–1.34
Total Cholesterol (mmol/L):
,5.0 1 ,0.001
5.0–6.9 0.61 0.59–0.62
$7.0 1.36 1.32–1.41
HDL Cholesterol (mmol/L):
#1.2 1 ,0.001
1.3–1.4 0.78 0.76–0.80
1.5–1.7 0.63 0.61–0.65
$1.8 0.48 0.47–0.49
Systolic blood pressure (mm Hg):
,140 1 ,0.001
140–159 1.55 1.52–1.59
$160 1.74 1.68–1.81
Diastolic blood pressure (mm Hg):
,90 1 ,0.001
90–99 0.92 0.89–0.95
$100 0.86 0.79–0.93
Frequency of BP measurements:
0 1 ,0.001
1–3 3.73 3.61–3.85
$4 7.67 7.39–7.95
Eligibility for lipid lowering drugs
Familial Hypercholesterolaemia 5.38 4.33–6.67 ,0.001
TC/HDL$6 1.83 1.77–1.89 ,0.001
Diabetic$40 years 6.44 6.26–6.63 ,0.001
Ten year CVD risk $20% 3.01 2.94–3.09 ,0.001
All eligible 3.64 3.56–3.71 ,0.001
OR=odds ratio, CI = confidence interval.
Adjusted for clustering by practice.
*Referent is none or no disease.
doi:10.1371/journal.pone.0067611.t002
Table 3. Multivariable odds ratios for association between
individual patient risk factors and prescription of lipid
lowering drugs.
Multivariable models* Patients (n=365,718)
OR 95% CI P value
Age group:
#44 1 ,0.001
45–54 2.01 1.93–2.09
55–64 3.59 3.45–3.73
$65 4.21 4.05–4.39
Gender (Men vs Women) 1.46 1.42–1.49 ,0.001
Smoking status** 1.35 1.32–1.38 ,0.001
Diabetes** 4.49 4.35–4.64 ,0.001
Family history of CHD** 1.52 1.46–1.59 ,0.001
Antihypertensive drugs use** 1.46 1.43–1.50 ,0.001
Deprivation (Townsend fifth):
1 (least deprived) 1 ,0.001
2 1.03 1.00–1.06
3 1.03 0.99–1.06
4 1.09 1.05–1.12
5 (most deprived) 1.15 1.10–1.20
Total Cholesterol (mmol/L):
,5.0 1 ,0.001
5.0–6.9 0.81 0.79–0.83
$7.0 2.20 2.12–2.29
HDL Cholesterol (mmol/L):
#1.2 1 ,0.001
1.3–1.4 0.87 0.84–0.89
1.5–1.7 0.74 0.72–0.76
$1.8 0.57 0.56–0.60
Systolic blood pressure (mm Hg):
,140 1 ,0.001
140–159 1.09 1.07–1.12
$160 1.07 1.02–1.12
Diastolic blood pressure (mm Hg):
,90 1 ,0.001
90–99 0.93 0.90–0.96
$100 0.85 0.79–0.91
Frequency of BP measurements:
0 1 ,0.001
1–3 2.61 2.51–2.70
$4 4.24 4.06–4.42
Adjusted for clustering by practice.
*Each risk factor is independently adjusted for other risk factors.
**Referent is none or no disease.
doi:10.1371/journal.pone.0067611.t003
Factors Influencing Prescribing of Statins
PLOS ONE | www.plosone.org 6 July 2013 | Volume 8 | Issue 7 | e67611
likely that over two years, GPs would have an opportunity to
prescribe to the great majority of patients [57]. We also confirmed
a link between antihypertensive prescribing and statin prescribing
[49,56].
We found that most statins are prescribed to patients who are
not eligible for treatment. Overtreatment with statins has been
reported from the USA, with a majority of those on treatment not
meeting eligible under guidelines [58]. A study at a similar time
reported overuse of statins in Norway [49]. However guidelines
have changed substantially since this time. More recently, overuse
of statins has been reported in the Netherlands, where a study
reported that most patients on statins for primary prevention were
not eligible and in Spain about one third were ineligible
[49,59,60].
Overall we find more evidence to support the view that
prescribing of statins is influenced more by single risk factors
Table 4. Multivariable odds ratios for association between individual risk factors and lipid lowering drugs in eligible and ineligible
patients.
Multivariable model* Eligible patients (n =74,137) Ineligible patients (n=291,581)
OR 95% CI P value OR 95% CI P value
Age group:
#44 1 ,0.001 1 ,0.001
45–54 1.58 1.48–1.70 2.51 2.38–2.65
55–64 1.98 1.86–2.12 5.28 5.00–5.57
$65 1.75 1.63–1.88 7.41 7.00–7.84
Gender (Men vs Women) 1.13 1.08–1.18 ,0.001 1.59 1.55–1.63 ,0.001
Smoking status** 1.26 1.21–1.31 ,0.001 1.42 1.38–1.45 ,0.001
Diabetes** 3.43 3.27–3.59 ,0.001 8.86 7.90–9.94 ,0.001
Family history of CHD** 1.22 1.14–1.30 ,0.001 1.70 1.61–1.80 ,0.001
Antihypertensive drugs use** 1.26 1.21–1.31 ,0.001 1.61 1.57–1.66 ,0.001
Deprivation (Townsend fifth):
1 (least deprived) 1 ,0.001 1 0.002
2 1.06 1.01–1.12 1.02 0.98–1.06
3 1.05 0.99–1.11 1.01 0.97–1.05
4 1.12 1.06–1.19 1.06 1.01–1.11
5 (most deprived) 1.19 1.11–1.27 1.10 1.04–1.16
Total Cholesterol (mmol/L):
,5.0 1 ,0.001 1 ,0.001
5.0–6.9 1.09 1.05–1.14 0.65 0.65–0.70
$7.0 2.48 2.32–2.66 1.61 1.53–1.70
HDL Cholesterol (mmol/L):
#1.2 1 ,0.001 1 ,0.001
1.3–1.4 0.99 0.95–1.04 0.91 0.87–0.94
1.5–1.7 0.93 0.88–0.98 0.77 0.74–0.81
$1.8 0.85 0.79–0.92 0.61 0.58–0.64
Systolic blood pressure (mm Hg):
,140 1 0.05 1 ,0.001
140–159 1.02 0.98–1.07 1.12 1.09–1.16
$160 0.94 0.88–1.01 1.14 1.07–1.22
Diastolic blood pressure (mm Hg):
,90 1 0.002 1 ,0.001
90–99 0.94 0.89–0.99 0.91 0.87–0.95
$100 0.84 0.75–0.94 0.81 0.73–0.89
Frequency of BP measurements:
0 1 ,0.001 1 ,0.001
1–3 3.15 2.95–3.37 2.35 2.25–2.45
$4 4.96 4.60–5.37 3.88 3.69–4.09
Adjusted for clustering by practice.
*Each risk factor is independently adjusted for other risk factors.
**Referent is none or no disease.
doi:10.1371/journal.pone.0067611.t004
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treated as categories (age $65 years; diabetes; total cholesterol
$7 mmol/L) and frequency of contact with a clinician than by
calculated CVD risk. The result is that there is a poor match
between eligibility for lipid lowering treatment and being
prescribed it.
Previous studies have shown variation in adherence to guidance
in routine clinical practice [61]. Guidelines for assessment and
follow up may be impractical [62]. Addressing the patient’s
primary concern may be a higher priority than prevention [63].
Clinicians and their patients may judge the costs and benefits of
treatment differently to guideline authors. The Framingham
equation overestimates the risk in populations with low CVD
rates, which could justify lower use of statins [64]. Degree of
adherence to guidelines may vary by health care centres [65].
Physicians who trained more recently are more likely to be
guideline adherent [66]. As our anonymised data includes no
information on general practitioner characteristics, we are unable
to investigate the relationship between physician characteristics
and prescribing.
The cost and cost-effectiveness implications of divergence from
statins guidelines may be substantial [67]. Improving guideline
compliance therefore has considerable potential to improve the
cost effectiveness of prevention.
Implication for future research
We should investigate whether poor discrimination in prescrib-
ing lipid lowering drugs extends to secondary prevention and to
antihypertensive prescribing. Our findings are adjusted for the
effects of practice, but the role of practice and GP characteristics
on guideline adherence requires further analysis. While analysis of
this kind can identify the importance of patient characteristics in
influencing prescribing behaviour, it does not explain why or how
these patient characteristics exert an influence. Divergence
between prescribing behaviour and guidelines may reflect GPs’
considered views about the effectiveness or adverse effects of
treatment in relation to specific patient characteristics (e.g.
prescribing to diabetics under the age of 40 years). If so these
beliefs should be identified and tested against empirical evidence.
If divergence between GP prescribing behaviour and guidelines
may reflects lack of awareness of existing evidence (e.g. that lipid
lowering drugs are effective in women), this can be addressed
through better research dissemination. There is now strong
evidence for the effectiveness of statins in primary prevention
[68]. If the problem is mainly practical – (e.g. GPs only
remembering to consider lipid lowering drugs in patients on
antihypertensive treatment or having their blood pressure
measured) the solutions may be practical steps such as electronic
reminders. This analysis is therefore a first step in understanding
why evidence based clinical guidelines do not translate into
prescribing behaviour and represents a model for investigating the
prescribing impact of other clinical guidelines.
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